Literature DB >> 24297942

Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.

Christophe Le Tourneau1, Xavier Paoletti, Elodie Coquan, Marie-Paule Sablin, Mustapha Zoubir, Ian F Tannock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24297942     DOI： 10.1200/JCO.2013.53.5518

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.

Authors:  Clémence Basse; Claire Morel; Céline Callens; Gaëlle Pierron; Vincent Servois; Anne Vincent-Salomon; Aude Jobard; Marie Alt; Francesco Ricci; Delphine Loirat; Marie-Paule Sablin; Marie Bretagne; Mathilde Saint-Ghislain; Ségolène Hescot; Anthony Gonçalves; Olivier Tredan; Coraline Dubot; Céline Gavoille; Jean-Pierre Delord; Mario Campone; Nicolas Isambert; Lisa Belin; Ivan Bieche; Maud Kamal; Christophe Le Tourneau
Journal:  JCO Precis Oncol       Date:  2018-10-19

2.  A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.

Authors:  A Spreafico; J-P Delord; L De Mattos-Arruda; Y Berge; J Rodon; E Cottura; P L Bedard; M Akimov; H Lu; S Pain; A Kaag; L L Siu; J Cortes
Journal:  Br J Cancer       Date:  2015-01-27       Impact factor: 7.640

3.  Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.

Authors:  M G Krebs; J-Y Blay; C Le Tourneau; D Hong; L Veronese; M Antoniou; I Bennett
Journal:  ESMO Open       Date:  2021-03-04

4.  CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.

Authors:  P Gougis; M Carton; C Tchokothe; M Campone; F Dalenc; A Mailliez; C Levy; W Jacot; M Debled; M Leheurteur; T Bachelot; A Hennequin; C Perrin; A Gonçalves; L Uwer; J C Eymard; T Petit; M A Mouret-Reynier; E Chamorey; G Simon; M Saghatchian; C Cailliot; C Le Tourneau
Journal:  Breast       Date:  2019-10-19       Impact factor: 4.380

5.  Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.

Authors:  Sarina A Piha-Paul; Matthew H Taylor; Daniel Spitz; Lee Schwartzberg; J Thaddeus Beck; Todd M Bauer; Funda Meric-Bernstam; Das Purkayastha; Linda Karpiak; Sebastian Szpakowski; Fadi Braiteh
Journal:  Oncotarget       Date:  2019-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.